TG Therapeutics reports stable or improved disability in 89% of evaluable patients in Phase 1 azer-cel MS trial at Day 90
TGTX•TG Therapeutics reported that 89% of evaluable patients in its Phase 1 azer-cel trial for progressive multiple sclerosis had stable or improved disability at Day 90. The 26-participant study reported no dose-limiting or high-grade CAR T-cell-related toxicities; dose escalation and longer-term follow-up are ongoing.
1. Preliminary trial results
TG Therapeutics announced preliminary Phase 1 results for azer-cel in progressive multiple sclerosis. Most evaluable patients had stable or improved disability at Day 90, despite prior progression on high-efficacy therapies, including anti-CD20 treatments.
2. Safety and follow-up
The 26-participant study showed no dose-limiting toxicities or high-grade CAR T-cell-related toxicities. The findings are limited by the small study population and short follow-up, with dose escalation and longer-term follow-up ongoing.
